Immune targets in the tumor microenvironment treated by radiotherapy

Omer M. Ozpiskin, Lu Zhang, Jian-Jian Li

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after diagnosis, has the advantage of local tumor control with relatively less systematic side effects comparing to chemotherapy. However, the efficacy of RT is limited by acquired tumor resistance leading to the risks of relapse and metastasis. To further enhance the efficacy of RT, with the renaissances of targeted immunotherapy (TIT), increasing interests are raised on RT combined with TIT including cancer vaccines, T-cell therapy, and antibody-based immune checkpoint blockers (ICB) such as anti-CTLA-4 and anti-PD1/PD-L1. In achieving a significant synergy between RT and TIT, the dynamics of radiation-induced response in tumor cells and stromal cells, especially the cross-talk between tumor cells and immune cells in the irradiated tumor microenvironment (ITME) as highlighted in recent literature are to be elucidated. The abscopal effect refereeing the RT-induced priming function outside of ITME could be compromised by the immune-suppressive factors such as CD47 and PD-L1 on tumor cells and Treg induced or enhanced in the ITME. Cell surface receptors temporally or permanently induced and bioactive elements released from dead cells could serve antigenic source (radiation-associated antigenic proteins, RAAPs) to the host and have functions in immune regulation on the tumor. This review is attempted to summarize a cluster of factors that are inducible by radiation and targetable by antibodies, or have potential to be immune regulators to synergize tumor control with RT. Further characterization of immune regulators in ITME will deepen our understanding of the interplay among immune regulators in ITME and discover new effective targets for the combined modality with RT and TIT.

Original languageEnglish (US)
Pages (from-to)1215-1231
Number of pages17
JournalTheranostics
Volume9
Issue number5
DOIs
StatePublished - Jan 1 2019

Fingerprint

Tumor Microenvironment
Radiotherapy
Neoplasms
Immunotherapy
Radiation
Cancer Vaccines
Antibodies
Immunologic Factors
Cell Surface Receptors
Regulatory T-Lymphocytes
Stromal Cells
Cell- and Tissue-Based Therapy
Neoplasm Metastasis
T-Lymphocytes
Recurrence
Drug Therapy

Keywords

  • CD47
  • HER2
  • Immune regulation
  • PD-1
  • PD-L1
  • Radiation therapy; irradiated tumor microenvironment
  • Radiation-associated antigenic proteins
  • Tumor associated macrophage

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Immune targets in the tumor microenvironment treated by radiotherapy. / Ozpiskin, Omer M.; Zhang, Lu; Li, Jian-Jian.

In: Theranostics, Vol. 9, No. 5, 01.01.2019, p. 1215-1231.

Research output: Contribution to journalReview article

Ozpiskin, Omer M. ; Zhang, Lu ; Li, Jian-Jian. / Immune targets in the tumor microenvironment treated by radiotherapy. In: Theranostics. 2019 ; Vol. 9, No. 5. pp. 1215-1231.
@article{430e74cc0b1c46e294500a0cf1ee235a,
title = "Immune targets in the tumor microenvironment treated by radiotherapy",
abstract = "Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after diagnosis, has the advantage of local tumor control with relatively less systematic side effects comparing to chemotherapy. However, the efficacy of RT is limited by acquired tumor resistance leading to the risks of relapse and metastasis. To further enhance the efficacy of RT, with the renaissances of targeted immunotherapy (TIT), increasing interests are raised on RT combined with TIT including cancer vaccines, T-cell therapy, and antibody-based immune checkpoint blockers (ICB) such as anti-CTLA-4 and anti-PD1/PD-L1. In achieving a significant synergy between RT and TIT, the dynamics of radiation-induced response in tumor cells and stromal cells, especially the cross-talk between tumor cells and immune cells in the irradiated tumor microenvironment (ITME) as highlighted in recent literature are to be elucidated. The abscopal effect refereeing the RT-induced priming function outside of ITME could be compromised by the immune-suppressive factors such as CD47 and PD-L1 on tumor cells and Treg induced or enhanced in the ITME. Cell surface receptors temporally or permanently induced and bioactive elements released from dead cells could serve antigenic source (radiation-associated antigenic proteins, RAAPs) to the host and have functions in immune regulation on the tumor. This review is attempted to summarize a cluster of factors that are inducible by radiation and targetable by antibodies, or have potential to be immune regulators to synergize tumor control with RT. Further characterization of immune regulators in ITME will deepen our understanding of the interplay among immune regulators in ITME and discover new effective targets for the combined modality with RT and TIT.",
keywords = "CD47, HER2, Immune regulation, PD-1, PD-L1, Radiation therapy; irradiated tumor microenvironment, Radiation-associated antigenic proteins, Tumor associated macrophage",
author = "Ozpiskin, {Omer M.} and Lu Zhang and Jian-Jian Li",
year = "2019",
month = "1",
day = "1",
doi = "10.7150/thno.32648",
language = "English (US)",
volume = "9",
pages = "1215--1231",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "5",

}

TY - JOUR

T1 - Immune targets in the tumor microenvironment treated by radiotherapy

AU - Ozpiskin, Omer M.

AU - Zhang, Lu

AU - Li, Jian-Jian

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after diagnosis, has the advantage of local tumor control with relatively less systematic side effects comparing to chemotherapy. However, the efficacy of RT is limited by acquired tumor resistance leading to the risks of relapse and metastasis. To further enhance the efficacy of RT, with the renaissances of targeted immunotherapy (TIT), increasing interests are raised on RT combined with TIT including cancer vaccines, T-cell therapy, and antibody-based immune checkpoint blockers (ICB) such as anti-CTLA-4 and anti-PD1/PD-L1. In achieving a significant synergy between RT and TIT, the dynamics of radiation-induced response in tumor cells and stromal cells, especially the cross-talk between tumor cells and immune cells in the irradiated tumor microenvironment (ITME) as highlighted in recent literature are to be elucidated. The abscopal effect refereeing the RT-induced priming function outside of ITME could be compromised by the immune-suppressive factors such as CD47 and PD-L1 on tumor cells and Treg induced or enhanced in the ITME. Cell surface receptors temporally or permanently induced and bioactive elements released from dead cells could serve antigenic source (radiation-associated antigenic proteins, RAAPs) to the host and have functions in immune regulation on the tumor. This review is attempted to summarize a cluster of factors that are inducible by radiation and targetable by antibodies, or have potential to be immune regulators to synergize tumor control with RT. Further characterization of immune regulators in ITME will deepen our understanding of the interplay among immune regulators in ITME and discover new effective targets for the combined modality with RT and TIT.

AB - Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after diagnosis, has the advantage of local tumor control with relatively less systematic side effects comparing to chemotherapy. However, the efficacy of RT is limited by acquired tumor resistance leading to the risks of relapse and metastasis. To further enhance the efficacy of RT, with the renaissances of targeted immunotherapy (TIT), increasing interests are raised on RT combined with TIT including cancer vaccines, T-cell therapy, and antibody-based immune checkpoint blockers (ICB) such as anti-CTLA-4 and anti-PD1/PD-L1. In achieving a significant synergy between RT and TIT, the dynamics of radiation-induced response in tumor cells and stromal cells, especially the cross-talk between tumor cells and immune cells in the irradiated tumor microenvironment (ITME) as highlighted in recent literature are to be elucidated. The abscopal effect refereeing the RT-induced priming function outside of ITME could be compromised by the immune-suppressive factors such as CD47 and PD-L1 on tumor cells and Treg induced or enhanced in the ITME. Cell surface receptors temporally or permanently induced and bioactive elements released from dead cells could serve antigenic source (radiation-associated antigenic proteins, RAAPs) to the host and have functions in immune regulation on the tumor. This review is attempted to summarize a cluster of factors that are inducible by radiation and targetable by antibodies, or have potential to be immune regulators to synergize tumor control with RT. Further characterization of immune regulators in ITME will deepen our understanding of the interplay among immune regulators in ITME and discover new effective targets for the combined modality with RT and TIT.

KW - CD47

KW - HER2

KW - Immune regulation

KW - PD-1

KW - PD-L1

KW - Radiation therapy; irradiated tumor microenvironment

KW - Radiation-associated antigenic proteins

KW - Tumor associated macrophage

UR - http://www.scopus.com/inward/record.url?scp=85062865125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062865125&partnerID=8YFLogxK

U2 - 10.7150/thno.32648

DO - 10.7150/thno.32648

M3 - Review article

VL - 9

SP - 1215

EP - 1231

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 5

ER -